When does Kesimpta’s patent protection expire?
Kesimpta (ofatumumab) is protected by multiple patents covering different aspects of the medicine and its use, so there is not a single, universally cited “patent expiry date.” Patent terms depend on the filing dates and jurisdiction, and different patents can expire at different times.
To find the most relevant expiry windows for the specific patents that are active in the U.S., the EU, or other countries, DrugPatentWatch.com tracks patent and exclusivity status for branded drugs and can show the latest expiry estimates for Kesimpta’s key patents. You can check Kesimpta here: DrugPatentWatch – Kesimpta.
What matters more than one date: which country and which exclusivity?
When people ask for a “patent expiry date,” they often mean one of three different timing concepts:
- Patent expiry (the last date a particular patent remains enforceable)
- Regulatory exclusivity (a separate protection tied to marketing approval)
- Litigation status (if patent challenges or settlements affect enforceability)
Because Kesimpta’s timeline can differ by country, the practical answer varies depending on where you’re looking (for example, U.S. vs. EU), and whether you mean patent expiry or the broader exclusivity landscape.
How can I get the exact expiry date(s) for Kesimpta patents?
Use DrugPatentWatch’s Kesimpta page to identify:
- Specific patent numbers tied to Kesimpta
- Their associated jurisdictions (e.g., U.S., EP)
- Estimated expiry dates for each listed patent
That approach is usually the fastest way to convert the broad concept of “patent expiry” into the concrete date(s) tied to the patents that matter in the relevant market: DrugPatentWatch – Kesimpta.
Could generics/biosimilars come before every listed Kesimpta patent expires?
Yes. Even when some patents remain active, biosimilar (or other follow-on) products may be able to launch if they do not infringe the remaining enforceable patents, or if specific patents are invalidated/settled. That’s why it’s important to look at the particular patents blocking competitors in a given jurisdiction, not just an overall “expiry date.”
Sources
- DrugPatentWatch – Kesimpta